Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD.

Nature. 2001 Apr 26;410(6832):1107-11.

PMID:
11323675
2.

Adaptive immunity maintains occult cancer in an equilibrium state.

Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD.

Nature. 2007 Dec 6;450(7171):903-7. Epub 2007 Nov 18.

PMID:
18026089
3.

MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice.

Engel AM, Svane IM, Rygaard J, Werdelin O.

Scand J Immunol. 1997 May;45(5):463-70.

4.
5.
6.
7.
8.
9.

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen YS, Shea LK, Hundal J, Wendl MC, Demeter R, Wylie T, Allison JP, Smyth MJ, Old LJ, Mardis ER, Schreiber RD.

Nature. 2012 Feb 8;482(7385):400-4. doi: 10.1038/nature10755.

10.

Failure of immunogenic tumors to elicit cytolytic T cells in syngeneic hosts.

Nelson DS, Hopper KE, Blanden RV, Gardner ID, Kearney R.

Cancer Lett. 1978 Aug;5(2):61-7.

PMID:
308390
11.

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

Garcia-Lora A, Martinez M, Algarra I, Gaforio JJ, Garrido F.

Int J Cancer. 2003 Sep 10;106(4):521-7.

13.

Modulation of antitumour immune responses by intratumoural Stat1 expression.

Messina NL, Banks KM, Vidacs E, Martin BP, Long F, Christiansen AJ, Smyth MJ, Clarke CJ, Johnstone RW.

Immunol Cell Biol. 2013 Oct;91(9):556-67. doi: 10.1038/icb.2013.41. Epub 2013 Aug 20.

PMID:
23958683
15.
16.

Interferon-gamma and cancer immunoediting.

Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD.

Immunol Res. 2005;32(1-3):231-45. Review.

PMID:
16106075
17.

Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1.

Lou Y, Seipp RP, Cai B, Chen SS, Vitalis TZ, Choi KB, Jeffries AP, Gopaul RS, Li XL, Seliger B, Pearson TW, Jefferies WA.

Vaccine. 2007 Mar 8;25(12):2331-9. Epub 2006 Dec 12.

PMID:
17229499
18.

Transfection of major histocompatibility complex class I and class II genes causes tumour rejection.

Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA.

J Immunogenet. 1989 Aug-Oct;16(4-5):343-9.

PMID:
2639907
19.

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61.

20.

Monoclonal antibodies against murine IFN-gamma abrogate in vivo tumor immunity against RSV-induced murine sarcomas.

Prat M, Bretti S, Amedeo M, Landolfo S, Comoglio PM.

J Immunol. 1987 Jun 15;138(12):4530-3.

PMID:
3035023

Supplemental Content

Support Center